File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
  • Basic View
  • Metadata View
  • XML View
TitleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
 
AuthorsPhua, KB1
Lim, FS3
Lau, YL2
Nelson, EAS9
Huang, LM5
Quak, SH6
Lee, BW7
Doorn, LJV8
Teoh, YL3 4
Tang, H4
Suryakiran, PV4
Smolenov, IV4
Bock, HL4
Han, HH4
 
Keywords3Years
Efficacy
Gastroenteritis
Rix4414
Rotavirus
 
Issue Date2012
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2012, v. 30 n. 30, p. 4552-4557 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2012.03.030
 
AbstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
 
ISSN0264-410X
2013 Impact Factor: 3.485
 
DOIhttp://dx.doi.org/10.1016/j.vaccine.2012.03.030
 
ISI Accession Number IDWOS:000310117100020
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorPhua, KB
 
dc.contributor.authorLim, FS
 
dc.contributor.authorLau, YL
 
dc.contributor.authorNelson, EAS
 
dc.contributor.authorHuang, LM
 
dc.contributor.authorQuak, SH
 
dc.contributor.authorLee, BW
 
dc.contributor.authorDoorn, LJV
 
dc.contributor.authorTeoh, YL
 
dc.contributor.authorTang, H
 
dc.contributor.authorSuryakiran, PV
 
dc.contributor.authorSmolenov, IV
 
dc.contributor.authorBock, HL
 
dc.contributor.authorHan, HH
 
dc.date.accessioned2012-10-30T06:09:11Z
 
dc.date.available2012-10-30T06:09:11Z
 
dc.date.issued2012
 
dc.description.abstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2012, v. 30 n. 30, p. 4552-4557 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2012.03.030
 
dc.identifier.citeulike10784864
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2012.03.030
 
dc.identifier.epage4557
 
dc.identifier.isiWOS:000310117100020
 
dc.identifier.issn0264-410X
2013 Impact Factor: 3.485
 
dc.identifier.issue30
 
dc.identifier.pmid22497874
 
dc.identifier.scopuseid_2-s2.0-84862020627
 
dc.identifier.spage4552
 
dc.identifier.urihttp://hdl.handle.net/10722/170465
 
dc.identifier.volume30
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.subject3Years
 
dc.subjectEfficacy
 
dc.subjectGastroenteritis
 
dc.subjectRix4414
 
dc.subjectRotavirus
 
dc.titleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Phua, KB</contributor.author>
<contributor.author>Lim, FS</contributor.author>
<contributor.author>Lau, YL</contributor.author>
<contributor.author>Nelson, EAS</contributor.author>
<contributor.author>Huang, LM</contributor.author>
<contributor.author>Quak, SH</contributor.author>
<contributor.author>Lee, BW</contributor.author>
<contributor.author>Doorn, LJV</contributor.author>
<contributor.author>Teoh, YL</contributor.author>
<contributor.author>Tang, H</contributor.author>
<contributor.author>Suryakiran, PV</contributor.author>
<contributor.author>Smolenov, IV</contributor.author>
<contributor.author>Bock, HL</contributor.author>
<contributor.author>Han, HH</contributor.author>
<date.accessioned>2012-10-30T06:09:11Z</date.accessioned>
<date.available>2012-10-30T06:09:11Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Vaccine, 2012, v. 30 n. 30, p. 4552-4557</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/170465</identifier.uri>
<description.abstract>RIX4414 (Rotarix&#8482;), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. &#169; 2012 Elsevier Ltd.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<subject>3Years</subject>
<subject>Efficacy</subject>
<subject>Gastroenteritis</subject>
<subject>Rix4414</subject>
<subject>Rotavirus</subject>
<title>Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.vaccine.2012.03.030</identifier.doi>
<identifier.pmid>22497874</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84862020627</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84862020627&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>30</identifier.volume>
<identifier.issue>30</identifier.issue>
<identifier.spage>4552</identifier.spage>
<identifier.epage>4557</identifier.epage>
<identifier.isi>WOS:000310117100020</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>10784864</identifier.citeulike>
</item>
Author Affiliations
  1. KK Women's And Children's Hospital
  2. The University of Hong Kong
  3. National Healthcare Group Polyclinics, Singapore
  4. GlaxoSmithKline
  5. National Taiwan University Hospital
  6. National University of Singapore
  7. Mount Elizabeth Medical Centre
  8. Delft Diagnostic Laboratory
  9. Chinese University of Hong Kong